Join us Thursday, Sept. 28 at 10:00 AM ET for the next presentation of our Global Cancer Research and; Control Seminar Series – NCI Center for Global Health

Fiona Hamilton Marshall: These are hopeful findings for patients with relapsed/refractory diffuse large B-cell lymphomawho may not have a durable response to existing therapies.

TIGIT bispecific program is advancing in clinical trials for non-small cell lung and gastric cancers. – Agenus

Asger Jakobsen: How do DNMT3A and TET2 mutant clones impact human haematopoiesis?  

Shernan Holtan: We hope the need for years and years of immunosuppression due to Graft-versus-host disease is gone forever

Nickolas Stabellini: Valuable insights into Health Disparities in CardioOncology and Cancer Research.

A potential new way to assess clinically valuable features of clear cell renal cell carcinoma (ccRCC)- Dana-Farber News.

Gemma Peters: This work is revolutionising how we think about meeting needs of patients and families at the end-of-life.

Jeff Ryckman: How many patients make it to CAR-T without ever seeing radiotherapy?

Josep Tabernero: This research was born out of a patient’s concern.